Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 610072, China.
Sichuan Electric Power Hospital, Chengdu, 610065, China.
J Robot Surg. 2023 Aug;17(4):1659-1667. doi: 10.1007/s11701-023-01576-0. Epub 2023 Mar 22.
To summarize surgical experiences with a new modified technique involving extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy based on Da Vinci SI system by reviewing case data, including follow ups, and to evaluate the safety and clinical efficacy of the surgical procedure. The case data from December 2020 to September 2022 of 321 patients undergoing modified single incision (without dedicated PORT) robotic-assisted laparoscopic radical prostatectomy via an extraperitoneal approach were reviewed. All procedures were performed by the same surgeon at our center. Perioperative data and postoperative urinary control, tumor control, and erectile function recovery were assessed. The immediate, 3-months, 6-months, 12-months, 18-months and 24-months complete urinary control rates were 34.3%, 56.6%, 79.7%, 85.7%, 89.6% and 90.7%, respectively; the 3-months, 6-months, 12-months, 18-months and 24-months biochemical recurrence rates were 3.4%, 5.2%, 9.1%, 21.7% and 30.2%, respectively; and for those with normal preoperative erectile function, the 3-months, 6-months, 12-months, 18-months and 24-months postoperative erectile function recovery rates were 52.2%, 60.0%, 70.7%, 72.2% and 73.9%, respectively. The new modified technique involving extraperitoneal single-incision robotic-assisted laparoscopic radical prostatectomy is safe and feasible. This technique has satisfactory surgical results, and this new method results in satisfactory urinary control, tumor control and recovery of erectile function. In addition, this new method is not limited to specific dedicated access devices, which facilitates its application.
总结了一项新改良技术的手术经验,该技术涉及达芬奇 Si 系统下经腹膜外单切口机器人辅助腹腔镜根治性前列腺切除术,通过回顾病例数据,包括随访结果,评估手术的安全性和临床疗效。回顾了 2020 年 12 月至 2022 年 9 月期间 321 例接受改良单切口(无专用 PORT)经腹膜外入路机器人辅助腹腔镜根治性前列腺切除术的患者的病例数据。所有手术均由中心的同一位外科医生完成。评估围手术期数据和术后尿控、肿瘤控制和勃起功能恢复情况。即时、3 个月、6 个月、12 个月、18 个月和 24 个月完全尿控率分别为 34.3%、56.6%、79.7%、85.7%、89.6%和 90.7%;3 个月、6 个月、12 个月、18 个月和 24 个月生化复发率分别为 3.4%、5.2%、9.1%、21.7%和 30.2%;对于术前勃起功能正常的患者,术后 3 个月、6 个月、12 个月、18 个月和 24 个月勃起功能恢复率分别为 52.2%、60.0%、70.7%、72.2%和 73.9%。经腹膜外单切口机器人辅助腹腔镜根治性前列腺切除术的新改良技术安全可行。该技术具有满意的手术效果,新方法尿控、肿瘤控制和勃起功能恢复效果满意。此外,该新方法不受特定专用通道设备的限制,便于应用。